Raphaëlle Richieri

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

Trial of Psilocybin versus Escitalopram for Depression

Major depressive disorder

Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants

REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics

Suicide and suicidal behaviour

Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development

Suicidality and Activation of the Kynurenine Pathway of Tryptophan Metabolism

A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders

Modified Mediterranean Diet for Enrichment of Short Chain Fatty Acids: Potential Adjunctive Therapeutic to Target Immune and Metabolic Dysfunction in Schizophrenia?

The role of short-chain fatty acids in microbiota–gut–brain communication

The neural basis of psychedelic action

<p>Ketamine and depression: a narrative review</p>

Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

The promise of ketamine for treatment‐resistant depression: current evidence and future directions

Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines

Preparing for the Bursting of the Psychedelic Hype Bubble

Ketamine administration in depressive disorders: a systematic review and meta-analysis

Sensory gating in adult with attention-deficit/hyperactivity disorder: Event-evoked potential and perceptual experience reports comparisons with schizophrenia

Fiabilité des références diagnostiques du Recueil d'Informations Médicalisées en Psychiatrie

[Analysis of the reliability of diagnostic criteria and classifications in psychiatry].